Silo Pharma, Inc. (NASDAQ:SILO) on Wednesday released results for its preclinical study evaluating SP-26. SP-26 is a ketamine ...

Successfully demonstrates strong tolerability, sustained drug release and safety SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE ...

H.C. Wainwright & Co. is acting as manager. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart ...

A Sarasota biopharmaceutical company is applying for a patent for an Alzheimer’s drug. Silo Pharma, based on North Washington ...

Silo Pharma (NASDAQ: SILO) today announced favorable preclinical results for SP-26, its novel extended-release ketamine implant aimed at treating fib ...

SARASOTA, FL, April 28, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics ...

SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo,” or the “Company”), a developmental stage biopharmaceutical company ...

Silo Pharma’s SP-26 met all preclinical endpoints and aims to qualify for the FDA’s streamlined 505(b)(2) pathway. Don't face extreme market conditions unprepared. Get the professional edge ...

SARASOTA, FL, April 30, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) ("Silo,” or the "Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug ...